InsuQuick VDPen contains Insulin Aspart (100 IU/ml), a rapid-acting insulin analog indicated for the management of hyperglycemia in patients with diabetes mellitus. Insulin Aspart facilitates glucose uptake into peripheral tissues and inhibits hepatic glucose production, thereby aiding in the regulation of blood glucose levels. The rapid onset of action, typically within 10-20 minutes post subcutaneous administration, allows for improved postprandial glucose control compared to regular human insulin. InsuQuick VDPen is designed for subcutaneous injection and is suitable for use in adults, adolescents, and children with type 1 diabetes, as well as adults with type 2 diabetes requiring insulin therapy. The prefilled, variable-dose pen device offers precise dosing flexibility, enhancing patient adherence and convenience. Dosage and administration should be individualized based on patient’s metabolic needs, blood glucose monitoring results, and glycemic control goals. InsuQuick VDPen should be used in conjunction with appropriate dietary measures and physical activity. Caution is advised to avoid hypoglycemia, the most common adverse effect. Proper injection technique and site rotation are recommended to minimize local reactions. Patients should be educated on recognizing and managing hypoglycemia and the importance of adherence to prescribed regimens for optimal therapeutic outcomes.